335 related articles for article (PubMed ID: 10064010)
1. Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Wegner CD; Cox BF
Thromb Haemost; 1999 Feb; 81(2):301-5. PubMed ID: 10064010
[TBL] [Abstract][Full Text] [Related]
2. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Henkin J
Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
[TBL] [Abstract][Full Text] [Related]
3. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial.
Ouriel K; Kandarpa K; Schuerr DM; Hultquist M; Hodkinson G; Wallin B
J Vasc Interv Radiol; 1999 Sep; 10(8):1083-91. PubMed ID: 10496712
[TBL] [Abstract][Full Text] [Related]
4. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
5. Recombinant pro-urokinase requires heparin for optimal clot lysis and restoration of blood flow in a canine femoral artery thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Henkin J
Thromb Haemost; 1993 Apr; 69(4):375-80. PubMed ID: 8497850
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase.
Credo RB; Burke SE
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):8S-18S. PubMed ID: 8770836
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
[TBL] [Abstract][Full Text] [Related]
9. Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.
Nakada MT; Montgomery MO; Nedelman MA; Guerrero JL; Cohen SA; Barnathan ES; Jordan RE
J Vasc Interv Radiol; 2004 Feb; 15(2 Pt 1):169-76. PubMed ID: 14963184
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis.
Badylak SF; Voytik SL; Henkin J; Burke SE; Sasahara AA; Simmons A
Thromb Res; 1991 May; 62(3):115-26. PubMed ID: 1716378
[TBL] [Abstract][Full Text] [Related]
11. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic application of contrast-enhanced ultrasound and low-dose urokinase for thrombolysis in a porcine model of acute peripheral arterial occlusion.
Ebben HP; Nederhoed JH; Slikkerveer J; Kamp O; Tangelder GW; Musters RJ; Wisselink W; Yeung KK
J Vasc Surg; 2015 Aug; 62(2):477-85. PubMed ID: 24768365
[TBL] [Abstract][Full Text] [Related]
13. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
[TBL] [Abstract][Full Text] [Related]
14. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
[TBL] [Abstract][Full Text] [Related]
15. Regional low dosage thrombolytic therapy for peripheral arterial occlusions.
Hallett JW; Yrizarry JM; Greenwood LH
Surg Gynecol Obstet; 1983 Feb; 156(2):148-54. PubMed ID: 6218633
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.
Furlan A; Higashida R; Wechsler L; Gent M; Rowley H; Kase C; Pessin M; Ahuja A; Callahan F; Clark WM; Silver F; Rivera F
JAMA; 1999 Dec; 282(21):2003-11. PubMed ID: 10591382
[TBL] [Abstract][Full Text] [Related]
17. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Lu HR; Lijnen HR; Stassen JM; Collen D
Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
[TBL] [Abstract][Full Text] [Related]
18. [Local thrombolysis in peripheral arterial occlusion].
Hess H
Herz; 1989 Feb; 14(1):12-21. PubMed ID: 2522076
[TBL] [Abstract][Full Text] [Related]
19. Intra-arterial prourokinase for acute ischemic stroke.
Akins PT
JAMA; 2000 Apr; 283(16):2102; author reply 2103-4. PubMed ID: 10791495
[No Abstract] [Full Text] [Related]
20. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
Mellott MJ; Connolly TM; York SJ; Bush LR
Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
